Stock Events

Stock Events

DBV Technologies 

0
135
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Oct 28Expected
Q1 2026
Q2 2026
Q3 2026
-0.05
-0.04
-0.03
-0.02
Expected EPS
-0.04737955011244
Actual EPS
-0.025469808304122

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-125.15MNet Income

Analyst Ratings

$35.28Average Price Target
The highest estimate is ⁦35.66⁩.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
50%
Hold
50%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow DBVA.STU. It's not an investment recommendation.
TotalEnergies
37
TTE.PA
Lvmh Moet Hennessy Louis Vuitton
24
MC.PA
Air Liquide
24
AI.PA
Engie
21
ENGI.PA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap95.99B
Regeneron Pharmaceuticals, involved in developing treatments for allergies and inflammatory diseases, competing in the broader allergy treatment market.
Sanofi
SNY
Mkt Cap106.24B
Sanofi, a large pharmaceutical company with a focus on immunology and allergy treatments, including collaborations on therapies that could compete with DBV's offerings.
Novavax
NVAX
Mkt Cap1.66B
Novavax, works on vaccines that could potentially address allergies, indirectly competing by targeting the underlying causes of allergic reactions.
Moderna
MRNA
Mkt Cap88.52B
Moderna, known for mRNA technology, which could be applied to develop vaccines or treatments for allergies, potentially competing with DBV's approach.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.33B
BioMarin Pharmaceutical, focuses on rare diseases but has interests in developing treatments that could overlap with allergy and immunotherapy markets.
Adma Biologics
ADMA
Mkt Cap2.56B
ADMA Biologics, specializes in immune globulin products which could be used in treating allergies, offering an alternative to DBV's therapies.
Vertex Pharmaceuticals
VRTX
Mkt Cap141.65B
Vertex Pharmaceuticals, while primarily focused on cystic fibrosis, its research into other areas of medicine could lead to competitive treatments in the allergy space.
GSK
GSK
Mkt Cap99.19B
GlaxoSmithKline, a large pharmaceutical company with a diverse portfolio, including respiratory and allergy treatments, potentially competing across several areas of DBV's interest.

About

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
Show More
CEO
Daniel Tassé
Employees
179
Country
France
ISIN
US23306J1016
WKN
000A40WEX

Listings

F
DE
DBV.F
F
DE
DBV1.F
STU
DE
DBV1.STU
STU
DE
DBV.STU

0 Comments

Share your thoughts

FAQs

What is DBV Technologies stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange DBV Technologies stocks are traded under the ticker DBVA.STU.
When is the next DBV Technologies earnings date?▼
DBV Technologies is going to release the next earnings report on March 11, 2027.
What were DBV Technologies earnings last quarter?▼
DBVA.STU earnings for the last quarter are -0.03 EUR per share, whereas the estimation was -0.05 EUR resulting in a +46.24% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is DBV Technologies revenue for the last year?▼
DBV Technologies revenue for the last year amounts to 0 EUR.
What is DBV Technologies net income for the last year?▼
DBVA.STU net income for the last year is -125.15M EUR.
How many employees does DBV Technologies have?▼
As of November 7, 2026, the company has 179 employees.
In which sector is DBV Technologies located?▼
DBV Technologies operates in the Health & Wellness sector.
When did DBV Technologies complete a stock split?▼
The last stock split for DBV Technologies was on June 7, 2024 with a ratio of 1:2.
Where is DBV Technologies headquartered?▼
DBV Technologies is headquartered in CHATILLON, France.